Study: This research is testing if high doses of testosterone can help prostate cancer patients with specific gene changes (ATM, CDK12, or CHEK2) related to DNA repair. These changes might make tumors more likely to respond to this treatment.

Details: The study is not blinded, meaning doctors and patients know the treatment being given. It focuses on patients with mCRPC, a type of prostate cancer that keeps growing even when testosterone levels are very low. Patients will take testosterone until their disease worsens or they can't handle the treatment. Doctors will monitor for side effects and check progress using scans and blood tests.

• Duration: Patients will receive treatment until they can't tolerate it or their cancer progresses.
• Visits: Regular check-ups and scans are required throughout the study.
• Eligibility: Male, over 18, with specific gene changes and prostate cancer history.

This study is for those who have tried other treatments without success and have minimal symptoms. It is important to discuss with your doctor about potential benefits and risks before joining.